Bcl-2 overexpression is an important mechanism underlying the aggressive behavior of prostate cancer cells and their resistance to radio-or chemotherapy. HA14-1, a recently discovered organic Bcl-2 inhibitor, potently induces apoptosis in various human cancer cells. Sequential exposure of radioresistant LNCaP (wild-type (wt) p53), LNCaP/Bcl-2 (wt p53) and PC3 (mutant p53) prostate cancer cells to a minimally cytotoxic concentration of 10 lM HA14-1 for 1 h followed by 1-6 Gy gamma radiation, resulted in a highly synergistic (combination index o1.0) induction of cell death as determined by an apoptosis assay at 72 h, and a clonogenicity assay at 12 days, after the initial treatment. The reverse treatment sequence did not cause a synergistic induction of cell death. When compared to individual treatments, cell death induced by the combined treatment was associated with dramatically increased reactive oxygen species (ROS) generation, c-Jun N-terminal kinase (JNK) activation, Bcl-2 phosphorylation, cytochrome c release, caspase-3 activation and DNA fragmentation. Exposure to either 200 lg/ml of the antioxidant alpha-tocopherol or 10 lM JNK inhibitor SP600125 before the combined treatment resulted in decreased activation of JNK and caspase-3 as well as decreased DNA fragmentation. However, treatment with the pancaspase inhibitor carbobenzoxyl-valylalanyl-aspartyl-[O-methyl]-fluoromethylketone before the combined treatment inhibited apoptosis without affecting JNK activation, and this inhibitory effect was enhanced in the presence of alpha-tocopherol or SP600125. Taken together, our results indicate that HA14-1 potently sensitizes radioresistant LNCaP and PC3 cells to gamma radiation, regardless of the status of p53. ROS and JNK are important early signals that trigger both caspasedependent and -independent cell death pathways and contribute to the apoptotic synergy induced by the combined treatments.
Introduction
Apoptosis is the primary mechanism that causes prostate cancer cells to die when subjected to radiotherapy (Denmeade et al., 1996; Szostak and Kyprianou, 2000) . However, resistant clones exist because of the overexpression of the antiapoptotic protein Bcl-2, which is inherent and/or results from prolonged exposure to cytotoxic treatment conditions (Tang and Porter, 1997; Autorino et al., 2003; Shaffer and Scher, 2003) . Bcl-2 overexpression is frequently found in both primary and metastatic human prostate cancers (Bauer et al., 1996; Krajewska et al., 1996) . Primary tumors that overexpress Bcl-2 exhibit a high Gleason score and a high rate of cancer recurrence after radical prostatectomy (Krajewska et al., 1996; Hering et al., 2001) . Following prolonged androgen ablation, chemo-or radiotherapy, Bcl-2 expression is often upregulated and associated with the development of androgen-, chemo-or radioresistance that ultimately leads to a less favorable progression (Raffo et al., 1995; Catz and Johnson, 2003; Rosser et al., 2003) . The most definitive evidence supporting a positive correlation between Bcl-2 and prostate cancer progression is that Bcl-2-transfected prostate cancer cells with de novo Bcl-2 overexpression exhibit metastatic and chemo-or radioresistant phenotypes (McConkey et al., 1996; Chaudhary et al., 2001) . Reversal of prostate cancer cell resistance to radiation has been achieved in vitro by downregulating Bcl-2 (Scott et al., 2002; Chendil et al., 2004) . Thus, Bcl-2 represents an attractive target for the development of new antiprostate cancer agents that have either direct cytotoxic effects on prostate cancer cells or improve the efficacy of conventional radio-or chemotherapy by sensitizing prostate cancer cells.
The antiapoptotic function of Bcl-2 is thought to reside in its binding to proapoptotic proteins, thus blocking their proapoptotic functions (Reed et al., 1996; Adams and Cory, 1998) . HA14-1 (C 17 H 17 BrN 2 O 5 , MW ¼ 409), ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate, is a synthetic organic molecule and a leading Bcl-2 inhibitor discovered recently by our group (Wang et al., 2000) . HA14-1 alone, or in combination with other cytotoxic agents, induces apoptosis selectively and effectively in many cell types including chemoresistant human cancer cells (Wang et al., 2000; Milella et al., 2002; Yamaguchi et al., 2002; Lickliter et al., 2003) . Studies indicate that apoptosis induced by HA14-1 involves changes in Ca 2 þ homeostasis, DCm, Bax translocation, reactive oxygen species (ROS) generation, cytochrome c release and caspase-9/-3 activation (Wang et al., 2000; An et al., 2004) . Given the unique mechanism of HA14-1 action, combining marginally cytotoxic concentrations of HA14-1 with other anticancer therapies may maximize the apoptotic effects against Bcl-2-overexpressing cancers while minimizing the nonspecific cytotoxic effects on normal tissues.
Radiation or radiotherapy is one treatment choice for regionally unresectable advanced prostate cancers and is also an adjuvant treatment of surgery (Szostak and Kyprianou, 2000) . However, successful treatment of cancer patients by radiotherapy largely depends on tumor radiosensitivity and the tolerance of normal tissues. To improve therapeutic outcomes, radiotherapy is often combined with chemotherapeutic drugs that are themselves cytotoxic and/or radiosensitizing (Garzotto et al., 1999; Lin et al., 2003; Belka et al., 2004) . This facilitates the use of radiotherapy at lower doses with higher efficacies. Although the precise molecular mechanism by which radiation triggers apoptotic or clonogenic cell death is not fully understood, the cytoplasmic membrane and DNA are the two major cellular targets (Higuchi, 2003; Mishra, 2004) . Damaging these cellular components induces ROS generation and DNA double-strand breaks (DSBs). Increasing evidence suggests that generation of ROS or DSBs caused by radiation eventually alters the function of the mitochondria where the predominant antiapoptotic protein Bcl-2 is expressed. It has been demonstrated that caspase, c-Jun N-terminal kinase (JNK) and p53 axes are particularly critical in radiationinduced cell death (Tournier et al., 2000; Fei and El-Deiry, 2003; Kolesnick and Fuks, 2003) . Bcl-2 overexpression retards or attenuates cell death caused by activation of the above signaling pathways in response to radiation (Park et al., 1997; Tepper et al., 1999; Zhan et al., 1999) . Therefore, selective targeting of Bcl-2 may improve the outcomes of radiotherapy (Kimura et al., 1999) .
In this study, we examined the apoptotic effects of HA14-1 alone and in combination with gamma radiation on radioresistant LNCaP, LNCaP/Bcl-2 and PC3 cells. In particular, we evaluated whether marginal cytotoxic doses of HA14-1 had any sensitizing effects on the induction of apoptosis in response to clinically relevant fractional doses (p2 Gy) of gamma radiation. We observed that ROS, JNK and caspase signaling play critical roles in the sensitizing and synergistic effects of HA14-1 on gamma radiation. This report represents the first description of a combined treatment based on targeting Bcl-2 by the small organic molecule HA14-1 to overcome the radioresistance of human LNCaP prostate cancer cells to apoptosis.
Results

HA14-1 by itself induces apoptosis in human LNCaP and
LNCaP/Bcl-2 prostate cancer cells LNCaP, LNCaP/Bcl-2 and PC3 cells were treated with various concentrations of HA14-1 for 6 h. At the end of each treatment, cell viability was determined by CellTiter 96 AQ assay (Promega, Madison, WI, USA). Between 50 and 80% of the LNCaP and 40 and 75% of the LNCaP/Bcl-2 cells lost their viability after a 6-h treatment with 30-50 mM HA14-1 (Figure 1a) . The cell death induced by 30-50 mM HA14-1 was associated with pronounced cytochrome c release (Figure 1b ) and caspase-3 activation (Figure 1c ) at 1 h, and DNA fragmentation (Figure 1d ) at 6 h. Although the 10 mM HA14-1 treatment produced a less than 5% cell death rate (Figure 1a) , elevated levels of ROS generation ( Figure 2a ) and caspase-3 activation ( Figure 1c ) were observed within 1 h compared to vehicle controls. A 1-h long pretreatment with 200 mg/ml alpha-tocopherol, followed by a 6-h treatment of 20 mM of HA14-1, resulted in attenuated ROS generation and completely blocked cell death (Figure 2b ). Targeting Bcl-2-mediated radiosensitization J An et al
Marginal cytotoxic dose of HA14-1 sensitizes LNCaP cells to gamma radiation LNCaP and LNCaP/Bcl-2 cells were exposed to 10 mM HA14-1 alone, 1-6 Gy gamma radiation alone or sequential combinations of HA14-1 with each dose of gamma radiation. The cell viability was determined by CellTiter 96 AQ assay (Promega), and the clonogenic cell survival was measured by the 12-day colony assay. Exposure of LNCaP or LNCaP/Bcl-2 cells to HA14-1 or gamma radiation alone for 72 h resulted in minimal apoptotic cell death. However, sequential exposure of LNCaP or LNCaP/Bcl-2 cells to 10 mM HA14-1 for 1 h followed by 1-6 Gy gamma radiation dramatically increased the induction of apoptosis at 72 h ( Figure 3a) and produced significant clonogenic cell death at day 12 (Figure 3b ). The combination indexes (CIs) were o1.0, indicative of synergism. LNCaP/Bcl-2 cells required a higher concentration of HA14-1 (data not shown) or a higher dose of radiation (Figure 3a and b) to achieve the same degree of cell death as that observed in LNCaP cells treated with the same doses of gamma radiation, or with the same concentration of HA14-1. The cell death caused by these combined treatments was dependent on the treatment sequence: pretreatment with 1-6 Gy gamma radiation for 1 h followed by HA14-1 for 72 h produced a minor enhancement in apoptosis.
Wild-type p53 does not appear to be essential for HA14-1 or HA14-1 plus radiation-induced apoptosis In addition to LNCaP cells that have wild-type (wt) p53, PC3 cells bear mutant p53. After exposure to HA14-1 alone, 1-6 Gy gamma radiation alone or sequential combinations of HA14-1 with each dose of gamma radiation, the cell death pattern of PC3 cells was comparable to that of LNCaP cells. Between 60 and 80% of the PC3 cells lost their viability after a 6-h treatment with 30-50 mM HA14-1 (Figure 4a) . Moreover, dramatic increases in the induction of apoptosis at 72 h ( Figure 4b ) and clonogenic cell death at day 12 ( Figure 4c ) were also observed after sequential exposure of PC3 cells to 10 mM_HA14-1 for 1 h followed by 1-6 Gy gamma radiation. Synergism was achieved as indicated by the CIs o1.0.
HA14-1 interrupts Bcl-2/Bax heterodimerization As shown in Figure 5 , treatment of LNCaP/Bcl-2 cells with HA14-1 at 25, 50 and 100 mM in vitro resulted in a There was no change in the total amount of Bcl-2 or Bax in the same lysates, indicating that HA14-1 treatment does not affect the levels of Bcl-2 and Bax expression.
HA14-1 pretreatment enhances cytochrome c release, caspase-3 activation and DNA fragmentation in response to gamma radiation Treatment with 10 mM HA14-1 or 2 Gy gamma radiation alone produced a slight increase in caspase-3 activation above baseline levels at 1 and 24 h compared to vehicle treatment controls. However, combined treatments with 10 mM HA14-1 plus 2 Gy gamma radiation produced not only an early small increase in caspase-3 activation at 1 h, but also a later pronounced increase at 24 h compared to treatments with the vehicle control, the 10 mM HA14-1 alone or the 2 Gy gamma radiation alone ( Figure 6a ). In parallel, pronounced cytochrome c release ( Figure 6b ) at 24 h and DNA fragmentation ( Figure 6c ) at 72 h were observed after combined treatments with 10 mM HA14-1 plus 1 or 2 Gy gamma radiation. However, cytochrome c release ( Figure 6b ) and DNA fragmentation ( Figure 6c ) were absent from the Western blotting assay following 24 and 72 h treatments with 10 mM HA14-1 or 2 Gy gamma radiation alone. Furthermore, comparisons with the vehicle treatment controls by flow cytometric analysis demonstrated that the percentage of cells that exhibited cytochrome c release was approximately (1) 471.6% after 1 h and 672% after 24 h treatments with 10 mM HA14-1 alone, (2) 070.5% after 1 h and 572% after 24 h treatments with 2 Gy gamma radiation alone and (3) 5076.8% after a 24 h treatment with 10 mM HA14-1 plus 2 Gy gamma radiation.
ROS, JNK and caspase-3 signaling are critical for apoptotic synergy of HA14-1 and gamma radiation To determine the degree of overall oxidative stress, ROS were monitored using 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (H 2 DCFDA). Oxidation of H 2 DCFDA leads to increases in the fluorescent product dichlorodihydrofluorescein, permitting quantification of relative levels of ROS. We examined the intracellular levels of ROS generated over time and analysed their correlation with the activation of JNK and caspase-3, and the percentage of cell death. After combined treatments with 10 mM HA14-1 followed by 1 or 2 Gy gamma radiation, biphasic patterns of ROS generation were observed (Figure 7a ) at 1 and 24 h, respectively. The occurrence of this biphasic pattern of ROS generation coincided with caspase-3 activation (Figure 6a) . Pretreatment with 200 mg/ml of the antioxidant alphatocopherol significantly attenuated the activation of caspase-3 ( Figure 7b ) and JNK as well as Bcl-2 phosphorylation at 1 h ( Figure 8a ) and cell death at 72 h (Figure 7c ) in response to the combined treatment. A maximal protective effect on apoptosis occurred after exposure of cells to alpha-tocopherol 1 h before, but not 1 h after, the HA14-1 treatment. Similarly, exposure of cells to 10 mM JNK inhibitor SP600125, 1 h before, but not 1 h after HA14-1, potently inhibited JNK activation at 1 h (Figure 8a ), impaired caspase-3 activation at 24 h ( Figure 8b ) and attenuated cell death at 72 h (Figure 8c ) caused by the combined treatment. However, the JNK activation and Bcl-2 phosphorylation could not be Targeting Bcl-2-mediated radiosensitization J An et al detected by the Western blot after treatment with a sensitizing dose of HA14-1 alone or 2 Gy radiation alone (data not shown). JNK activation remained unchanged after pre-exposure of cells to 20 mM carbobenzoxyl-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (z-VAD-fmk) followed by combined treatment of HA14-1 and 2 Gy gamma radiation (Figure 8a ), and apoptosis was not completely inhibited following the above treatment (Figures 7c and 8c) . A maximum inhibitory effect was achieved by the addition of 100 mg/ml alpha-tocopherol (Figure 7c ) or 5 mM SP600125 (Figure 8c ) to the 10 mM z-VAD-fmk pretreatment.
Discussion
Bcl-2 overexpression is critical for the growth of prostate cancer cells and the suppression of apoptosis caused by many death stimuli including radiotherapy (Scherr et al., 1999; Rosser et al., 2003) . In this study, we demonstrated that overcoming radioresistance in LNCaP, LNCaP/Bcl-2 and PC3 prostate cancer cells was achievable by HA14-1, a recently discovered smallmolecule inhibitor of Bcl-2 (Wang et al., 2000; Milella et al., 2002; Yamaguchi et al., 2002) . Our results showed that treatment with HA14-1 alone at concentrations of 30-50 mM for 6 h was sufficient to kill 50-80% of LNCaP, 40-75% of LNCaP/Bcl-2 and 60-80% of PC3 cells (Figures 1a and 4a) . It was associated with typical apoptotic characteristics such as caspase-3 activation ( Figure 1c ) and DNA fragmentation (Figure 1d ). Although HA14-1 alone at 10 mM or gamma radiation alone at 1-6 Gy produced only marginal cytotoxic effects, sequential exposure of LNCaP or LNCaP/Bcl-2 cells to 10 mM HA14-1 for 1 h followed by 1-6 Gy gamma radiation resulted in a synergistic (CIo1.0) increase in cell death (Figure 3a and b) . This synergistic cell death was especially associated with biphasic increases in both ROS generation (Figure 7a ) and caspase-3 activation (Figure 6a ) at 1 and 24 h. Exposure to 200 mg/ml alpha-tocopherol, an antioxidant, or 10 mM SP600125, a JNK inhibitor, before the HA14-1 treatment significantly decreased JNK (Figure 8a ) and caspase-3 (Figure 7b ) activation and cell death (Figure 7c ). However, treatment with the pancaspase inhibitor, z-VAD-fmk, before the combined treatment inhibited apoptosis (Figure 8c ) without affecting JNK activation (Figure 8a) , whereas the protective effect of z-VAD-fmk on apoptosis was enhanced by the pretreatment with alpha-tocopherol (Figure 7c ) or SP600125 (Figure 8c ). These results suggest that the early oxidative injury and activation of JNK and caspase-3 are attributed to HA14-1 sensitizing LNCaP cells to gamma radiation.
Radiation or radiotherapy is an important treatment choice for locally or regionally advanced prostate cancer (Szostak and Kyprianou, 2000) . However, the radioresistance of prostate cancer cells is a practical limitation of radiotherapy. Therefore, to improve therapeutic outcomes, radiotherapy is often combined with other agents that are either cytotoxic, radiosensitizing or both (Garzotto et al., 1999; Lin et al., 2003; Belka et al., 2004) . Such combinations increase the sensitivity of tumor cells to lower doses of both radiation and anticancer drugs while reducing cytotoxic effects on Figure 6 Enhanced cytochrome c release and caspase-3 activation are responsible for the dramatically increased cell death caused by sequential combined treatments. (a) After combined treatments with 10 mM HA14-1 and 2 Gy gamma radiation, biphasic patterns of caspase-3 activation were generated: an early small increase at 1 h (*Po0.05) and a later pronounced increase at 24 h (**Po0.01). Targeting Bcl-2-mediated radiosensitization J An et al normal cells and improving the therapeutic index of the chemo-radiotherapy. LNCaP prostate cancer cells are highly radioresistant. Less than 10% of these cells die up to 72 h after exposure to 8-20 Gy of radiation (Kimura et al., 1999) . Consistent with these published data, our results indicated that less than 5-20% of LNCaP and 0-3% of LNCaP/Bcl-2 cells were dead 72 h after exposure to 1-6 Gy of gamma irradiation alone (Figure 3a) . However, one cycle of 1 or 2 Gy gamma radiation preceded by 10 mM HA14-1 caused loss of viability in more than 60-80% of LNCaP and 55-80% of LNCaP/Bcl-2 cells at 72 h after treatment (Figure 3a) . The dose of HA14-1 used to obtain this synergistic effect with gamma radiation has considerably fewer side effects on normal tissues (Todaro et al., 2002; Lickliter et al., 2003) . The chosen low radiation doses are based on a regimen of clinical application that delivers 2 Gy fractions to the prostate over a 5-7-week period (for a total of 60-70 Gy) (Hahn et al., 1996) . This use of a marginally cytotoxic dose of HA14-1 combined with clinically relevant fractionated doses (1 or 2 Gy) of gamma radiation delivered locally may minimize systemic side effects caused by HA14-1 while maximizing local tumor tissue-restricted cytotoxic effects that result from such a combined treatment. Sensitization of radioresistant LNCaP or LNCaP/Bcl-2 cells by HA14-1 is crucial for the synergistic cell death caused by the sequential combinations of HA14-1 and Role of ROS in apoptotic synergy in response to sequential combined treatments. (a) As was the case with caspase-3 activation, after treatments with 10 mM HA14-1 followed by 2 Gy gamma radiation, a small but statistically significant increase in ROS generation was observed at 1 h (*Po0.05) and a pronounced increase at 24 h (**Po0.01), when compared to individual treatments. Each value is the mean7s.d. of three separate experiments. (b) Single exposure to 200 mg/ml alpha-tocopherol (lane 2) or 20 mM z-VAD (lane 3) 1 h before the 10 mM HA14-1 treatment resulted in attenuated caspase-3 activation at 24 h in response to 2 Gy gamma radiation. However, an obvious caspase-3 activation was observed in cells after treatment with 10 mM HA14-1 plus 2 Gy gamma radiation without the presence of alphatocopherol (lane 1). (c) alpha-Tocopherol (100 mg/ml) and z-VAD-fmk (10 mM) each separately inhibited the apoptotic effects of the combined treatment when cells were exposed to them 1 h before, but not 1 h after, the HA14-1 treatment. Moreover, this inhibitory effect on apoptosis was further enhanced by the concurrent treatment of cells with both 100 mg/ml alpha-tocopherol and 10 mM z-VAD-fmk.
Targeting Bcl-2-mediated radiosensitization J An et al gamma radiation. Although the early increases in ROS and caspase-3 activation in response to 10 mM HA14-1 pretreatment may help to initiate a sublethal apoptotic signal that lowers the apoptotic threshold, but may be insufficient for the progression of apoptosis without additional cytotoxic stimulation. The important role of HA14-1 pretreatment is supported by our observations that (1) the levels of ROS production and caspase-3 activation increased in cells within 1 h after individual treatments with 10 mM HA14-1 (Figures 1c, 2a, 6a and 7a), (2) dramatically increased ROS production (Figure 7a ), JNK (Figure 8a ) and caspase-3 activation (Figure 6a) , as well as cell death (Figure 3a and b) , were observed after sequential exposure of cells to HA14-1 for 1 h followed by gamma radiation but not after the reverse treatment sequence and (3) a maximal inhibitory effect against apoptosis was obtained after concurrent exposure of cells to alpha-tocopherol, SP600125 and z-VAD-fmk 1 h before, but not 1 h after, the combined treatment (Figures 7c and 8c) .
The generation of ROS caused by the combined treatment contributes to both caspase-dependent and -independent cell death. In this study, we found that caspase-3 activation and cell death in response to the combined treatment was significantly prevented by pretreatment with alpha-tocopherol, indicating that caspase-dependent cell death caused by the combined treatment was ROS-mediated. Moreover, the enhanced antiapoptotic effect of z-VAD-fmk (10 mM) against the combined treatment caused by the addition of alpha-tocopherol (100 mg/ml) suggests that ROS may also be involved in mediating caspaseindependent apoptosis (Figure 7c ). The role of ROS in apoptosis has been demonstrated extensively (Phillips et al., 2002; Mikkelsen and Wardman, 2003; An et al., 2004) . Upon death stimulation, ROS can induce an oxidative damage series including direct attacks on cell membranes and DNA leading to loss of membrane integrity and DNA single-strand breaks (SSBs) or DSBs (Higuchi, 2003) . The SSBs or DSBs are critical for triggering p53-mediated Bax translocation and caspase-3 activation-dependent apoptosis (Fei and El-Deiry, 2003) . However, wt p53 does not appear to be essential for HA14-1-or HA14-1 plus radiation-induced apoptosis (Figure 4a-c) .
Clonogenic cell death is thought to be the predominant mechanism of cell death caused by radiation (Dewey et al., 1971) . Unrepaired or misrepaired DSBs are lethal lesions associated with clonogenic cell death, usually occurring after several mitotic cycles (Dewey et al., 1971) . Comparisons of the frequencies of apoptotic cell death (Figure 3a ) and clonogenic survival (Figure 3b ) indicated that combined treatment predominantly produced direct cytotoxic effects on prostate cancer cells as well as on clonogenic cells. In cells plated immediately after exposure to gamma radiation, the frequency of cells that lost their clonogenicity was comparable to that of cells that lost their viability. However, the deceased colony count was partially owing to the formation of clusters (o40 cells), which may result from cell cycle arrest instead of clonogenic cell death, as the cells grew in a delayed rather than a discontinuous manner (data not shown). The direct killing caused by the sequentially combined treatments may reduce the incidence of clonal survival of prostate cancer cells that escape from the lethal or sublethal effects of radiation. These results, together with data published previously by others and by us (Wang et al., 2000; Milella et al., 2002; Yamaguchi et al., 2002; Lickliter et al., 2003) , provide a strong biologic rationale for using this new class of drugs in combination with radiotherapy or other chemotherapy. However, the relationship between cell cycle perturbation and ROS, JNK or SDBs in LNCaP cell death in response to the combined treatment needs to be further evaluated.
JNK activation is required for the combined treatment-induced apoptosis and is independent of caspase-3 activation. JNK participates in the induction of apoptosis in various cellular systems exposed to different stimulations including chemotherapeutic drugs and ionizing radiation (Ortiz et al., 2001; Lin and Dibling, 2002; Vivo et al., 2003; Xiao et al., 2004) . We showed that JNK was activated at 1 h by the combination of HA14-1 and radiation (Figure 8a ). In cells treated with HA14-1 plus radiation, JNK inhibition increased cell survival and significantly decreased apoptosis, because pretreatment with the JNK inhibitor SP600125 suppressed both caspase-3 activation ( Figure 8b ) and apoptosis (Figure 8c ), whereas pretreatment with the caspases-3 inhibitor z-VAD-fmk prevented apoptosis (Figures 7c and 8c) but not JNK activation. Thus, the JNK activation was independent of caspase-3. Caspase-3 may be dually regulated by apoptotic factors released from mitochondria and by a JNK metabolic pathway in LNCaP cells exposed to HA14-1 plus radiation. Nevertheless, the downstream mechanism that accounts for the proapoptotic actions of JNK induced by HA14-1 plus radiation needs to be further investigated. Our data indicated that SP600125, a reversible ATP-competitive JNK inhibitor, rescued HA14-1 plus radiation-induced cell death by suppressing the phosphorylation of the JNK substrate Bcl-2 (Figure 8a ). Recent new evidence indicates that the phosphorylation of Bcl-2, Bim or 14-3-3 by JNK is critical for promoting Bax translocation and subsequent cytochrome c release and capase-3 activation (Lei and Davis, 2003; Tsuruta et al., 2004) .
In summary, our results demonstrate that reversal of radioresistance in LNCaP (wt p53), LNCaP/Bcl-2 (wt p53) and PC3 (mutant p53) cells could be achieved by sequential exposure to a marginally cytotoxic concentration of HA14-1 followed by gamma radiation. This sequentially combined treatment produces a synergistic cytotoxic effect on both non-clonogenic and clonogenic cells. Our findings identify oxidative injury and JNK activation caused by the combined treatment as critical in triggering synergistic mitochondrial dysfunction, caspase activation and apoptosis. These data highlight the potential that small molecular inhibitors of Bcl-2, such as HA14-1 or its analogs, may be effective anticancer agents that merit further evaluation and development.
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Materials and methods
Reagents HA14-1 (ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate) was synthesized by our laboratory using a method published previously (Yu et al., 2000) . For the treatments, HA14-1 was freshly dissolved in dimethyl sulfoxide (DMSO) and an appropriate dilution in culture media was made just before use in each experiment. alpha-Tocopherol (Sigma, St Louis, MO, USA) and 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (H 2 DCFDA; Molecular Probes, Eugene, OR, USA) were dissolved in DMSO and ethanol, respectively; the aliquots were stored at À201C. 
Cell culture and treatment
The LNCaP and PC3 cell lines were purchased from the American Type Culture Collection. Each of LNCaP or LNCaP/Bcl-2 cell lines has been stably transfected with either pcDNA3-neo (control) or pcDNA3-Bcl-2 (obtained from Dr Hong-Gang Wang, H Lee Moffitt Cancer Institute, Tampa, FL, USA), respectively. Cells were cultured in Rosewell Park Memorial Institute media supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 800 mM/ml genticin (G418, Invitrogen, San Diego, CA, USA). The doses of radiation, HA14-1, the other agents used and the treatment intervals are indicated in Materials and methods and Results. Cells were maintained in a humidified 5% CO 2 atmosphere at 371C.
Gamma radiation
Cells at 10 6 /ml with or without a preincubation of different concentrations of HA14-1 or other agents were irradiated using 137 Cs g-ray source JL Shepherd Mark I Irradiator (JL Shepherd and Associates) with a dose rate of 0.354 Gy/min at room temperature. Non-irradiated controls were handled identically to the irradiated cells with the exception of the radiation treatment. After radiation, cells were processed for the assays described below. Each experiment was performed at least three times.
Measurement of cell viability
After different treatments as indicated in the Results section, cells were plated at 10 4 cells per well in 96-well plates. Cell viability was measured by using a CellTiter 96 AQ ueous assay kit (Promega) at 72 h after the initial treatments. According to the manufacturer's instructions, 20 ml of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium solution was added to 100 ml of culture media and incubated for 4 h at 371C. Afterward, the absorbance at 490 nm was measured using a Wallec Victor 2 multilable counter (Perkin-Elmer, Boston, MA, USA). Assays were performed in triplicate for each experiment; mean cell viability was compared to vehicle-treatment controls. Each experimental data point was generated from at least three independent experiments.
Assessment of clonogenicity
After gamma radiation, the cells of each treatment group were plated immediately at 10 2 -10 3 /well in a six-well plate and incubated for 12 days at 371C in a humidified atmosphere containing 5% CO 2 . Colonies containing more than 40 cells were scored on day 12. Individual assays were performed with duplicate wells, and repeated at least three times. Doseresponse clonogenic survival curves were platted on a loglinear scale. The surviving fraction at each dose was calculated by comparison to the colony number of the non-irradiated vehicle controls.
Measurement of cytochrome c release
Mitochondrial versus cytosol fractions of cells were prepared using a Mitochondrial/Cytosol Fractionation kit (Biovision, Mountain View, CA, USA). Cells at 5 Â 10 6 with or without different treatments were harvested by centrifugation at 700 g for 5 min. After washes with phosphate-buffered saline (PBS), the cells were resuspended in a 250 ml extraction buffer containing a protease inhibitor mixture and dithiothreitol (Biovision) and incubated on ice for 30 min. The cells were then homogenized using a Kontes Dounce tissue grinder (Fisher) on ice. The homogenates were centrifuged at 700 g for 10 min at 41C. The supernatant was collected and further centrifuged at 10 000 g for 30 min at 41C. The resulting supernatants were harvested and designated as cytosolic fractions, and the pellets were resuspended in an appropriate buffer and designated as mitochondrial fractions. The cytochrome c was analysed using Western blotting with cytochrome c monoclonal antibody or control antibody against b-actin. In addition, cytochrome c release was also measured by labeling digitonin-permeabilized cells with a fluoresein isothiocyanate (FITC)-conjugated anti-cytochrome c (clone 6H2.B4) antibody (Assay Designs, Ann Arbor, MI, USA) according to the method published by others (Marchal et al., 2004) . Briefly, after different treatments, the 0.5-1 Â 10 6 cells were trypsinized, washed and permeabilized with 0.1 mg/ml digitonin for 20 min at 41C, and then they were washed and stained with FITC-anti-cytochorme c for 15 min at room temperature. After being washed, the cells were measured using a flow cytometer with 488 nm excitation/ 535 nm emission.
Quantitative measurement of caspase activity Caspase-3 activity was determined using an Apo-ONE homogenous caspase-3/-7 assay kit (Promega), according to the manufacturer's instructions. Briefly, after different treatments, the 10 4 /100 ml cells were incubated with FITCconjugated Z-DEVD-R110 to detect caspase-3 activity. Following incubation for 30 min at 371C, the fluorescence intensity was determined using the Wallac Victor 2 multilable counter (Perkin-Elmer). The increase in the fluorescence intensity was determined by comparing the level of treated cells to that of vehicle controls.
Co-immunoprecipitation assays
After different treatments, the LNCaP/Bcl-2 cells were lysed in a Nonidet P-40 lysis buffer containing 10 mM HEPES, pH 7.5, 142.5 mM KCl, 5 mM MgCl 2 , 1 m ethyleneglycoltetraacetate, 0.2% Nonidet P-40, 0.1 mM phenylmethylsulfonyl fluoride and 5 mg/ml each of antipain, aprotinin and leupeptin. Immunoprecipitations (IPs) were performed by preincubation of the lysates for 1 h with protein G-agarose beads to remove any proteins that had bound nonspecifically to the protein G-agarose beads. After centrifugation, the supernatant was incubated with anti-Bcl-2 antibody overnight at 41C, and then protein G-agarose beads were added and incubated for another 2 h at 41C. The immune complexes isolated by centrifugation were washed, and boiled in SDS sample buffer for SDS-polyacrylamide gel electrophoresis (SDS-PAGE)/ immunoblot analysis with anti-Bax polyclonal antibody.
Western blotting analysis
After the required treatments, cells were washed with PBS and lysed in the sample buffer for SDS-PAGE. The protein concentrations, lysates or IP, were determined using the BioRad protein assay, and separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The blots were probed with each of the following primary antibodies: Bax, cytochrome c, caspase-3, phospho-Bcl-2, SAPK/JNK, phospho-SAPK/JNK (Thr 183 / Tyr 185 ) and the control antibody against b-actin. Signals were detected using the horseradish peroxidase-conjugated secondary antibody and enhanced chemiluminescence substrate kit (Amersham Pharmacia, Piscataway, NJ, USA).
Measurement of DNA fragmentation
After appropriate treatments, cells were harvested by centrifugation, washed with ice-cold PBS and placed in a lysis buffer containing 50 mM Tris (pH 8.0), 10 mM ethylenediaminetetraacetic acid, 0.5% SDS, 0.5% sodium chloride and 1 mg/ml proteinase K for 3 h at 561C. Then, an additional 1-h incubation was performed with 0.5 mg/ml RNase A at 371C. Finally, the DNA was precipitated with isopropanol and analysed by 2% agarose gel electrophoresis. After ethidium bromide staining, the presence of DNA in the gels was visualized under ultraviolet (UV) light.
Measurement of ROS generation
After different treatments as indicated in the Results section, the cells were loaded with 10 mM of H 2 DCFDA that was intracellularly de-esterified to dichlorodihydrofluorescein, the substrate that ROS oxidizes to fluorescent dichlorofluorescein. The fluorescent intensity was measured using either a FluroMax-2 fluorescence spectrofluorimeter (JoBin YvonSpex Instruments SA Inc., Edison, NJ, USA) or a Wallac 1420 Victor 2 multilable counter (Perkin-Elmer). Fluorescence was excited at 485 nm and emitted fluorescence was recorded at 538 nm.
Statistical analysis
The statistical analysis was performed using the Student's t-test. The P-values o0.05 were considered statistically significant. Average values were expressed as mean7s.d. The following equation was used to determine the combined cytotoxic effects of HA14-1 and gamma radiation according to the method of Chou and Talalay (1984) 
